CCDC114, DNAI2 and TOP2A are implicated in the effects of tibolone treatment on the postmenopausal endometrium | BMC Women’s Health
Luís Â, Domingues F. Effects of red clover on the blood lipid profile of perimenopausal and postmenopausal women: a meta-analysis. Climact J Int Menop Soc. 2018; 21 (5): 446–53.
Lee SN, Cho JY, Eun YM, Song SW, Moon KW. Associations between osteoporosis and coronary heart disease in postmenopausal women. Climact J Int Menop Soc. 2016; 19 (5): 5.
Google Scholar
Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020; 382 (5): 446–55.
Brinton LA, Trabert B, Anderson GL, Falk RT, Felix AS, Fuhrman BJ, Gass ML, Kuller LH, Pfeiffer RM, Rohan TE. Serum estrogen and estrogen metabolites and the risk of endometrial cancer in postmenopausal women. Cancer Epidemiol Biomark Prevent. 2016; 25 (7): 1081–9.
Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong the life of postmenopausal women. Int J Gyncol Obstet. 1993; 42 (2): 225-6.
Hanifi-Moghaddam P, Boers-Sijmons B, Klaassens AH, van Wijk FH, den Bakker MA, Ott MC, Shipley GL, Verheul HA, Kloosterboer HJ, Burger CW, et al. Molecular analysis of the human endometrium: Short-term tibolone signaling differs significantly from estrogen and estrogen + progestin signaling. J Mol Med (Berl). 2007; 85 (5): 471–80.
Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, Marata AM, Magrini N, D’Amico R, Bassi C, Maestri E. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016; 10 (10): CD008536.
Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and endometrial cancer risk: a systematic review. Maturities. 2016; 91: 25-35.
Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, den Hollander W, Stathopoulos V, Helmond FA. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007; 92 (3): 911-8.
Huang KE, Baber R. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric. 2010; 13 (4): 317–27.
Reis BF, Lima S, Silva G, Francisco A, Barbosa L, Archangelo S, Grande RM. Effects of low dose tibolone on steroid receptors and Bcl-2 on postmenopausal endometrium. Histol Histopathol. 2016; 31 (6): 629–34.
Hanifi-Moghaddam P, Boers-Sijmons B, Klaassens AHA, Wijk FH, Van BMA, Den OMC, Shipley GL, Verheul HAM, Kloosterboer HJ, Burger CW. Molecular analysis of the human endometrium: Short-term tibolone signaling differs significantly from estrogen and estrogen + progestin signaling. J Mol Med. 2007; 85 (5): 471–80.
Gautier L, Cope L, Bolstad BM, Irizarry RA. affy: Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20 (3): 307-15.
Smyth GK. limma: linear models for microarray data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S, editors. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005. p. 397-420.
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large lists of genes using DAVID’s bioinformatics resources. Nat Protoc. 2008; 4:44.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. The ontology of genes: a tool for unifying biology. Nat Genet. 2000; 25 (1): 25-9.
Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic acids Res. 2000; 28 (1): 27-30.
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP. STRING v10: protein-protein interaction networks, integrated on the tree of life. Nucleic Acids Res 2015; 43 (database problem): D447-52.
Yu Tang ML, Wang J, Pan Y, Wu FX. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of biological networks. BioSystems. 2014; 11: 005.
Google Scholar
Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003; 4: 2.
Cotto KC, Wagner AH, Feng YY, Kiwala S, Coffman AC, Spies G, Wollam A, Spies NC, Griffith OL, Griffith M .: DGIdb 3.0: a redesign and expansion of the drug-gene interactions database . Nucleic acids Res. 2018; 46 (D1): D1068–73.
Shang W, Burton JC, Behringer RR, Larina IV. : Functional optical coherence tomography for high resolution mapping of cilia beat frequency in the mouse oviduct in vivo. In: Photonic therapy and diagnosis XII: 2016; 2016.
Bylander A, Lind K, Goksör M, Billig H, Larsson DJ. The classic progesterone receptor mediates the rapid reduction in the rate of ciliary beatings of the fallopian tubes by progesterone. Reprod Biol Endocrinol. 2013; 11 (1): 33.
Haider S, Gamperl M, Burkard TR, Kunihs V, Kaindl U, Junttila S, Fiala C, Schmidt K, Mendjan S, Knöfler M. Estrogen signaling leads to ciliogenesis in human endometrial organoids. Endocrinology. 2019; 160 (10): 2282–97.
McClung EC, Berglund A, Welsh E, Xiong Y, Robertson S, Boac B, Chon HS, Magliocco A, Marchion D. Differential expression of cilia-related genes in endometrioid endometrial carcinoma: prognostic implications and therapeutic opportunities. Gyncol Oncol. 2016; 143 (1): 201.
Gur M, Cohen EB, Genin O, Fainsod A, Perles Z, Cinnamon Y. Roles of the gene associated with the cilium CCDC11 in left-right structuring and in laterality disorders in humans. Int J Dev Biol. 2017; 61 (3-4-5): 267.
Milla C. Exome sequencing identifies mutations in CCDC114 as the cause of primary ciliary dyskinesia. Am J Hum Genet. 2013; 92 (1): 99-106.
Paff T, Onoufriadis A, Anthony D, Shoemark A, Micha D, Kuyt B, Schmidts M, Petridi S, Dankert-Roelse JE, Haarman EG. The mutation of the CCDC114 gene causes primary ciliary dyskinesia with normal fertility in the isolated population of Volendam. Tijdschrift Voor Kindergeneeskunde. 2013; 81 (1): 92-92.
Loges NT, Olbrich H, Fenske L, Mussaffi H, Horvath J, Fliegauf M, Kuhl H, Baktai G, Peterffy E, Chodhari R. DNAI2 mutations cause primary ciliary dyskinesia with defects in the outer arm of dynein. Am J Hum Genet. 2008; 83 (5): 547–58.
Shorter SL, Albaghdadi AJH, Kan FWK. Alterations in the morphology of oviductal cilia and reduced expression of axonemal dynein in diabetic NOD mice. Tissue cell. 2016; 48 (6): 588–95.
Zhaojuan Y, Ji W. Mouse dynein axonemic intermediate chain 2: cloning and expression. DNA Cell Biol. 2008; 27 (9): 479–88.
Ganzina F. 4′-epi-doxorubicin, a novel doxorubicin analogue: a preliminary overview of preclinical and clinical data. Cancer Treat Rev. 1983; 10 (1): 1–22.
Cersosimo RJ, Hong WK. Epirubicin: review of the pharmacology, clinical activity and adverse effects of an adriamycin analogue. J Clin Oncol. 1986; 4 (3): 425-39.
Feher O, Vodvarka P, Jassem J, Morack G, Advani SH, Khoo KS, Doval DC, Ermisch S, Roychowdhury D, Miller MA. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 and over with metastatic breast cancer: a multicenter, randomized phase III study. Ann Oncol. 2005; 16 (6): 899-908.
Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mouridsen HT, Rose C, Nielsen OS. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels carried out by the Danish Breast Cancer Cooperative Group. J Clin Oncol. 1996; 14 (4): 1146–55.
Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubianamathieu N, den Boer MO. Randomized phase III trial comparing epirubicin and docetaxel sequentially with epirubicin alone in postmenopausal patients with lymph node breast cancer. J Clin Oncol. 2011; 29 (24): 3247–54.
Wils JA, Bliss JM, Marty M, Coombes G, Fontaine C, Morvan F, Olmos T, Perez-Lopez FR, Vassilopoulos P, Woods E. Epirubicin plus tamoxifen versus tamoxifen alone in postmenopausal lymph node patients with cancer Breast: a randomized trial of the International Collaborative Cancer Group. J Clin Oncol. 1999; 17 (7): 1988-98.
Lehne G, Deangelis P, Clausen O, Hall K, Huitfeldt H, Rugstad H. Pharmacokinetics and cytotoxicity of epirubicin (epi) in drug resistant human hepatoma cells (hb8065). Int J Oncol. 1994; 4 (6): 1229–35.
Tarpgaard LS, Qvortrup C, Nygård SB, Nielsen SL, Andersen DR, Jensen NF, Stenvang J, Detlefsen S, Brünner N, Pfeiffer P. A phase II study of epirubicin in oxaliplatin-resistant patients with cancer metastatic colorectal and amplification of the TOP2A gene. Bmc Cancer. 2016; 16 (1): 91.
Knoop A, Knudsen H, Balslev E, Rasmussen B, Overgaard J, Nielsen K, Schønau A, Gunnarsdóttir K, Mouridsen H, Ejlertsen B. 674 Topoisomerase II alpha (TOP2A) alterations as a predictive marker of epirubicin sensitivity in 805 high-risk changes in breast cancer patients. A randomized DBCG trial (DBCG89D). Eur J Cancer Suppl. 2003; 1 (5): S202-3.
Erica M, Christine D, Chiara B, Regan MM, Catherine O, Denis L, Francesca G, Martine PG, Christos S, Rimm DL. TOP2A protein by quantitative immunofluorescence as a predictor of the response to epirubicin in the neoadjuvant treatment of breast cancer. Future Oncol. 2013; 9 (10): 1477–87.
Ito F, Furukawa N, Nakai T. Evaluation of TOP2A as a predictive marker of endometrial cancer with adjuvant chemotherapy containing taxane. Int J Gynecol Cancer. 2016; 26 (2): 325-30.
